<DOC>
	<DOCNO>NCT00002643</DOCNO>
	<brief_summary>Phase II trial study effectiveness combination chemotherapy treat patient newly diagnose metastatic Ewing 's sarcoma primitive neuroectodermal tumor . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Newly Diagnosed Metastatic Ewing 's Sarcoma Primitive Neuroectodermal Tumor</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate response rate duration response patient newly diagnose , metastatic Ewing 's sarcoma primitive neuroectodermal tumor treat maximally intensify VAdrC ( vincristine , doxorubicin , cyclophosphamide ) alternate IE ( ifosfamide , etoposide ) . II . Evaluate response new agent ( first topotecan , topotecan cyclophosphamide ) utilize upfront treatment window . III . Assess role surgery regard local control primary metastatic site disease course . IV . Evaluate whether individual variability ifosfamide cyclophosphamide metabolism correlate toxicity and/or response . V. Evaluate rise absolute neutrophil count follow one dose filgrastim ( G-CSF ) give immediately prior chemotherapy course indicator bone marrow reserve subsequent myelosuppression . VI . Determine amifostine provide significant chemo-radio protection , particularly cumulative toxicity intensive therapy . OUTLINE : This partially randomize , multicenter study . Patients treat investigational window first proceed induction therapy immediately , aggressive treatment necessary . INVESTIGATIONAL WINDOW : Patients receive cyclophosphamide IV topotecan IV 30 minute day 1-5 . Filgrastim ( G-CSF ) administer subcutaneously ( SQ ) begin day 6 blood cell count recover . Treatment repeat week 3 . INDUCTION THERAPY : Patients 12 month old randomize receive amifostine . Patients receive etoposide IV 45 minute ifosfamide IV 2 hour day 1-5 . Amifostine IV 15 minute also administer prior ifosfamide . Patients receive G-CSF SQ ( IV 2 hour ) begin day 6 . This course treatment administer week 6 , 12 , 18 . Patients receive VAdrC chemotherapy regimen week 9 15 . This regimen consist vincristine IV amifostine IV 15 minute day 1 , 8 , 15 , cyclophosphamide IV 30 minute doxorubicin IV 48 hour day 1 2 , G-CSF begin day 3 . The VAdrC regimen continue local therapy week 21-29 39-47 , except day 15 dose vincristine omit , cyclophosphamide administer day 1 week 21 , 24 , 27 , 39 , 42 , 45 , doxorubicin replace etoposide IV 60 minute day 1-3 week 24 , 28 , 42 , 45 . Local therapy begin 21 week chemotherapy . Patients respond chemotherapy resectable disease undergo complete resection negative margin . Patients unresectable disease bulky lesion undergo radiotherapy . Some patient may undergo surgery radiotherapy . Local therapy metastasis delay week 39 . Patients follow every 3 month 1 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose , pathologically confirm Ewing 's sarcoma primitive neuroectodermal tumor ( PNET ) Diagnosis establish biopsy primary tumor Light microscopy ( hematoxylin eosin stain ) consistent Ewing 's sarcoma PNET No immunohistochemical ultrastructural characteristic inconsistent Ewing 's sarcoma PNET suggestive rhabdomyosarcoma Metastatic disease require Biopsy radiographically questionable metastasis ( e.g. , pulmonary lesion ) require Chest wall tumor separate pleural mass consider metastatic No positive pleural fluid cytology alone PATIENT CHARACTERISTICS : Age : 30 Absolute neutrophil count great 1,200/mm3 Platelet count great 120,000/mm3 Bilirubin less 1.5 mg/dL AST/ALT le 3 time normal Creatinine normal age Significant renal abnormality/disease eligible nuclear GFR normal study coordinator approve Echocardiogram MUGA normal PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy Resection diagnosis discourage exclude</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>neutropenia</keyword>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
</DOC>